Retatrutide for Weight Loss: The Next-Gen Drug, Explained
Retatrutide (“reta”) reached roughly 24% weight loss in trials — the most of any weight loss drug so far. Here’s what it is, how it stacks up against tirzepatide and semaglutide, and an honest answer on whether you can actually get it.
Last updated: Aug 16, 2026
First, the honest part
Retatrutide is not yet FDA-approvedand can’t be legitimately prescribed or purchased for weight loss. It’s in late-stage trials, with a possible approval in the 2026–2027 window. This page explains the science and how it compares — and points you to the approved options you can use today.
What is retatrutide?
Retatrutide is an investigational once-weekly injection from Eli Lilly. What makes it different is that it’s a triple agonist: it activates three receptors at once — GLP-1 and GIP (like tirzepatide) plus a third, glucagon. That extra target is thought to boost metabolism and fat burning on top of the appetite effects, which is why it has produced the largest weight loss seen in trials so far.
Retatrutide vs tirzepatide vs semaglutide
| Factor | Retatrutide | Tirzepatide / Semaglutide |
|---|---|---|
| Drug class | Triple agonist — GLP-1 + GIP + glucagon | See below |
| Average weight loss (trials) | Up to ~24% at 48 weeks (Phase 2) | Tirzepatide ~20%+ · Semaglutide ~15% |
| Format | Once-weekly injection | Once-weekly injection (both) |
| FDA status | Investigational — not yet approved | Tirzepatide & semaglutide are FDA-approved |
| Availability | Not available to prescribe yet | Available now via licensed providers |
Compare the approved options in our tirzepatide and semaglutide guides.
What the trials show
In a Phase 2 study published in 2023, participants on the highest retatrutide dose lost about 24% of their body weight over 48 weeks — ahead of tirzepatide (~20%) and semaglutide (~15%) in their own trials. Larger Phase 3 trials are now underway to confirm the effect and its long-term safety. Early results are promising, but Phase 3 outcomes and FDA review are what determine whether — and when — it reaches patients.
What you can use today
Since retatrutide isn’t available yet, the most effective approved options are tirzepatide (~20% weight loss) and semaglutide (~15%). Both are prescribed online by licensed telehealth providers, often as affordable compounded versions. Compare providers on pricing, medical support, and value.
Retatrutide: Frequently Asked Questions
What is retatrutide?
Retatrutide (sometimes called “reta” or a “triple agonist”) is an investigational once-weekly injection from Eli Lilly. Unlike semaglutide (a GLP-1) or tirzepatide (a dual GLP-1/GIP), retatrutide targets three receptors at once — GLP-1, GIP, and glucagon — which is why it has produced the largest weight loss of any drug in trials so far.
How much weight loss does retatrutide cause?
In a Phase 2 trial, participants on the highest dose lost about 24% of their body weight over 48 weeks — more than tirzepatide (~20%) or semaglutide (~15%) in their trials. These are early results; larger Phase 3 trials are underway to confirm them.
Is retatrutide FDA approved?
No. As of 2026, retatrutide is investigational and has not been approved by the FDA for weight loss or any other use. It is being studied in late-stage (Phase 3) clinical trials.
When will retatrutide be available?
It depends on the outcome of its Phase 3 program and FDA review. Industry expectations point to a potential approval in the 2026–2027 window, but timelines can shift. Until it's approved, it cannot be legitimately prescribed for weight loss.
Retatrutide vs tirzepatide — which is more effective?
In their respective trials, retatrutide produced more weight loss (~24%) than tirzepatide (~20%+). But tirzepatide is FDA-approved and available today, while retatrutide is still investigational. For most people the practical comparison is between the approved options — with retatrutide as a promising future addition.
Can you buy retatrutide now?
No. Because it isn't FDA-approved, retatrutide is not legitimately available to purchase or be prescribed for weight loss. Be cautious of any site claiming to sell “retatrutide” — sourcing an unapproved drug carries real safety and legal risks. Stick to approved medications prescribed by a licensed clinician.
Sources: Phase 2 retatrutide trial results (New England Journal of Medicine, 2023) and manufacturer trial program information; published data for tirzepatide (SURMOUNT) and semaglutide (STEP). Trial figures are averages; individual results vary. Brand and drug names are trademarks of their respective manufacturers.
topweightloss.io is not a medical provider and does not prescribe medications. This page is for educational purposes only and is not medical advice. Retatrutide is investigational and not FDA-approved. Always consult a licensed healthcare provider about approved treatment options.